Research Use Only - Not for human consumption. 18+ only.
Research CompoundKhavinson BioregulatorsOral

Pancragen

Also known as: Pancreatic Bioregulator

Pancragen is a Khavinson bioregulator tetrapeptide that regulates insulin synthesis and supports pancreatic function. It may improve glucose metabolism and maintain pancreatic cell health.

Research Status

Research Compound

Khavinson bioregulator - Russian research

For research purposes only. Not approved for human use. Not medical advice.

Research Areas

Supports pancreatic function
Regulates insulin synthesis
May improve glucose metabolism
Supports enzymatic activity
Maintains pancreatic cell health
Metabolic regulation

Side Effects

Gastrointestinal upset (nausea, mild abdominal discomfort)
UncommonMild

May occur when taken on an empty stomach. Typically resolves by taking with food or after meals. Usually self-limiting and does not require discontinuation.

Allergic reaction (rash, itching, swelling)
RareModerate

May occur in individuals with peptide sensitivity or shellfish allergy (some bioregulators are derived from marine sources). Discontinue immediately and seek medical attention if symptoms develop.

Hypoglycemia (low blood sugar)
RareSerious

Theoretically possible if Pancragen enhances insulin secretion in individuals with existing insulin sensitivity or diabetes. Monitor blood glucose if taking concurrently with antidiabetic medications. Seek immediate medical attention if symptoms of hypoglycemia develop (tremor, sweating, confusion, loss of consciousness).

Headache
UncommonMild

Occasionally reported in early use. Usually resolves within a few days as the body adjusts. Stay hydrated and consider over-the-counter analgesics if needed.

Dosing Reference

ParameterValue
Dose range10-20 mg
FrequencyDaily for 10-20 days
TimingWith meals
RouteOral

Cycle 10-20 days every 3-6 months. For metabolic support.

Research disclaimer

Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.

Reconstitution Guide

Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution

Do not shake the vial vigorously; gentle swirling prevents peptide degradation

Discard immediately if the solution appears cloudy, discolored, or contains visible particles

Use within 30 days of reconstitution when stored at 2–8°C

Do not freeze the reconstituted solution; freezing may denature the peptide

Use the PeptideVolt reconstitution calculator for your exact concentration

Use the PeptideVolt reconstitution calculator for your exact concentration

Molecular and Pharmacological Data

Pancragen is a Khavinson bioregulator tetrapeptide that acts as a tissue-specific regulator of pancreatic function. It is proposed to enhance insulin synthesis and secretion by supporting the metabolic activity of pancreatic beta cells, thereby improving glucose homeostasis and maintaining pancreatic cell health. The mechanism is believed to involve selective stimulation of gene expression in pancreatic tissue, promoting cellular differentiation and metabolic optimization.

Pancreatic Beta Cell Regulation

Pancragen is theorized to enhance insulin-producing beta cell function by promoting gene expression patterns that support insulin synthesis and secretion, thereby improving glucose-dependent insulin release.

Glucose Metabolism Support

By supporting pancreatic function, Pancragen may improve overall glucose metabolism and insulin sensitivity, contributing to better blood glucose control.

Tissue-Specific Bioregulation

As a Khavinson bioregulator, Pancragen is designed to selectively target pancreatic tissue and promote cellular homeostasis and metabolic optimization without systemic endocrine disruption.

  • Pancragen is a tetrapeptide (4 amino acid chain) derived from Khavinson's bioregulator research program
  • Bioregulators are proposed to work through selective tissue targeting and gene expression modulation rather than receptor-mediated mechanisms
  • Clinical evidence for Pancragen is limited; most data comes from Russian and Eastern European research with limited peer-reviewed publication in Western medical literature
  • The peptide is marketed primarily in Russia and select international markets; regulatory approval varies by country

Track your Pancragen research

Free account. No credit card required.

Start Free

Browse the Research Library

40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.

View all peptides

Research Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Pancragen is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.